Showing results (151-160 of 164) with videos related to
Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyLucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.Nature Cancer|February 14, 2024
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trialEvanthia T Roussos Torres, Won J Ho, Ludmila Danilova, et al.Science Translational Medicine|April 12, 2012
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profileJeffrey Hrkach, Daniel Von Hoff, Mir Mukkaram Ali, et al.Nature Communications|January 11, 2024
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial resultsGail D Lewis, Guangmin Li, Jun Guo, et al.The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.Cancer Treatment Reviews|May 21, 2019
Improving attribution of adverse events in oncology clinical trialsGoldy C George, Pedro C Barata, Alicyn Campbell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2022
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of ResponseTimothy A Yap, Justin F Gainor, Margaret K Callahan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.The New England Journal of Medicine|March 25, 2026
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic CancerWungki Park, Anup Kasi, Alexander I Spira, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2025
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I StudyAdrian G Sacher, Wilson H Miller, Manish R Patel, et al.Pageof 17